Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer

Background Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is infrequently offered to older individuals. This study determined if there are fit older patients with high-risk disease who may benefit from chemotherapy. Methods A multicentre, prospective, observational study was performed to determine chemotherapy (±trastuzumab) usage and survival and quality-of-life outcomes in EBC patients aged ≥70 years. Propensity score-matching adjusted for variation in baseline age, fitness and tumour stage. Results Three thousands four hundred sixteen women were recruited from 56 UK centres between 2013 and 2018. Two thousands eight hundred eleven (82%) had surgery. 1520/2811 (54%) had high-risk EBC and 2059/2811 (73%) were fit. Chemotherapy was given to 306/1100 (27.8%) fit patients with high-risk EBC. Unmatched comparison of chemotherapy versus no chemotherapy demonstrated reduced metastatic recurrence risk in high-risk patients(hazard ratio [HR] 0.36 [95% CI 0.19–0.68]) and in 541 age, stage and fitness-matched patients(adjusted HR 0.43 [95% CI 0.20–0.92]) but no benefit to overall survival (OS) or breast cancer-specific survival (BCSS) in either group. Chemotherapy improved survival in women with oestrogen receptor (ER)-negative cancer (OS: HR 0.20 [95% CI 0.08–0.49];BCSS: HR 0.12 [95% CI 0.03–0.44]).Transient negative quality-of-life impacts were observed. Conclusions Chemotherapy was associated with reduced risk of metastatic recurrence, but survival benefits were only seen in patients with ER-negative cancer. Quality-of-life impacts were significant but transient. Trial Registration ISRCTN 46099296

(RCTs) to evaluate the impact of systemic chemotherapy, the majority of trials excluded or recruited poorly amongst older patients, and tended to enrol fitter individuals. 6 This reflects clinicians' and patients' toxicity concerns and reticence from trialists about diluting the study power by introducing higher morbidity rates and competing causes of death in less fit older patients.
Older adults derive less benefit from chemotherapy compared to younger patients. Benefit is present between the ages of 70 and 80, although data for women aged over 80 years are scarce. 7 The Bridging the Age Gap study was designed to recruit a large, realworld, cohort of older women with breast cancer including detailed baseline fitness data and information about the cancer, treatment received and outcomes. The objectives of this study analysis were to determine health status-stratified outcomes for EBC patients aged ≥70 according to whether they received guideline concordant or non-concordant care with a particular focus on chemotherapy use. In this paper, the age-and risk-stratified patterns of receipt of adjuvant systemic therapy are described in older EBC patients, with propensity score-matched analysis of disease recurrence, survival and quality-of-life outcomes.

Study design
Bridging the Age Gap is a prospective multicentre, observational cohort study. Patients were recruited from 56 UK centres in England and Wales (Supplementary Table 1). Eligible patients were women ≥70 years at diagnosis of primary operable invasive breast cancer (TNM stages: T1-3 (plus some T4b), N0-1, M0). Those unsuitable for surgery or with previous EBC within five years were not eligible.
Baseline data collection Patients were recruited at the time of EBC diagnosis and before commencing treatment and could participate at three levels: full, partial (no requirement to complete quality of life [QoL] assessments) or by proxy (simple third-party data collection for those with cognitive impairment).
Baseline data were collected about the primary tumour including; cancer type, grade, nodal status, tumour size, oestrogen (ER), progesterone (PR) and human epidermal growth factor receptor 2 (HER2) status. Staging was performed if clinically indicated. Surgical, radiotherapy and systemic therapy data were collected.
Quality-of-life was assessed using the EuroQol-5D-5L (EQ-5D-5L). 14 Assessments on the European Organisation for the Research and Treatment of Cancer QoL Questionnaire (EORTC-QLQ)-C30, 15 EORTC-QLQ-BR23, 16 EORTC-QLQ-ELD15 17 were also collected but are presented elsewhere. 18 Follow-up and outcomes Patients were followed up at 6 weeks, and 6, 12, 18 and 24 months. Survival outcomes (date and cause of death) were obtained at 52 months median follow-up from the UK cancer registry. All patients were assessed for recurrence and QoL at each visit. Complications were categorised using the Common Terminology Criteria for Adverse Events system (CTCAE v4.0).
Chemotherapy-related mortality was defined as death within 30 days of chemotherapy or if chemotherapy was documented as a contributing cause. Deaths were categorised as disease related or other causes. Deaths were reviewed by the chief investigator blind to treatment decisions. Deaths were classified as disease related if the death was related to the initial breast cancer. Patients for whom the cause could not be established were excluded from cause-specific analyses.

Statistical analyses
Analyses were performed in IBM SPSS statistics version 24 and R version 3.6.3. 19 A p < 0.05 was considered statistically significant.
The relationships between systemic therapy use and tumour and patient characteristics were evaluated using uni-and multivariable logistic regression. High-risk EBC was defined if any of the following criteria were present: node-positive, ER-negative, HER2 positive, grade 3 or Recurrence Score ≥25. (Supplementary  Table 2a). Additional analyses were conducted in patients with ER-negative and HER2-positive tumours, where the benefits from chemotherapy might be anticipated. Fitness was defined based on geriatric assessments and categorised into fit, vulnerable and frail according to a cumulative score including measures of functional status, comorbidities, polypharmacy, nutritional status and cognitive status (Supplementary Table 2b).
Both overall survival (OS) and breast cancer-specific survival (BCSS) were compared in treated and untreated patients. A Cox proportional hazards model was fitted using regression-based adjustment based on covariates of: treatment; age; categories of aPG-SGA, ADL, IADL, CCI, MMSE, ECOG, medications and Nottingham Prognostic Index (NPI) 20 and HER2 for all high-risk patients. Hazard ratios (HR) and corresponding 95% confidence intervals (CIs) were calculated.
A propensity score adjustment among sufficiently similar highrisk patients was fitted using a Cox model with a shared frailty term (or random effect) for matched patients. Participants were matched exactly on NPI category and HER2 status, and logistic regression was used to calculate propensity scores for treatment in relation to age, aPG-SGA category, ADL category, IADL category, MMSE category, CCI category, ECOG PS category and number of medications. The ratio and calliper widths of the propensity scores were chosen following examination of the propensity score overlaps for several combinations of ratios and callipers. A 1:3 ratio for chemotherapy versus no chemotherapy and a calliper of 0.25 times the propensity scores' standard deviation was used to ensure participants were closely matched whilst retaining as many patients as possible.
The QoL questionnaires were scored according to the EQ-5D-5L User Guide (Version 3.0). 21 Missing data were managed accordingly. The QoL analysis included only patients with highrisk EBC as detailed in Supplementary Table 2a and where questionnaires were available. The mean difference (95% CI) of the domain scores at each time-point, adjusted for baseline scores, was calculated with linear regression models for high-risk participants. Propensity score-matching was also performed, as detailed above, to compare the EQ-5D-5L usual activities score in a matched cohort receiving chemotherapy versus patients not receiving it.

RESULTS
Between January 2013 and June 2018, 3456 women were recruited from 56 centres in England and Wales. This analysis was restricted to the 2811 women who underwent surgery within 6 months of diagnosis (STROBE diagram [ Fig. 1]). 22 Patients' characteristics according to geriatric assessments, tumour characteristics, postoperative histology and surgery performed are shown in Table 1 Table 2. Younger, less dependent patients with high-risk tumours and with fewer comorbidities were more likely to receive chemotherapy.
Additional post-hoc exploratory analyses were performed in disease subgroups. Out of 369 patients with ER-negative EBC and known mortality status, 132 (35.8%) received chemotherapy. In a propensity score-matched analysis in 136 patients, chemotherapy  Table 6 and Supplementary Fig. 2).
Supplementary Table 7 outlines chemotherapy toxicity. Among 397 patients receiving chemotherapy, there was one chemotherapy-related death (0.25%) (due to congestive heart failure) and 132 (33.2%) had an episode of infection, which was grade 3 or 4 in 50 (12.6%). Among the 163 patients who received trastuzumab, 4 (2.5%) experienced cardiac failure within the first 6 months and 12 (6.7%) within the first year.
Among 2811 patients undergoing surgery, the QoL analysis was restricted to 1520/2811 (54.1%) with high-risk EBC of whom 1315/ 1520 (86.5%) had an EQ-5D-5L score available at baseline. Of these patients, 376/1520 (24.7%) received chemotherapy. Health utilities were similar with estimated mean differences less than 0.02 units (p > 0.1), whereas the visual analogue scale (VAS) measures were significantly worse at 6 months in patients receiving chemotherapy versus not (adjusted mean difference −6.57, 95% CI −8.74 to −4.40, p < 0.001). Changes were no longer significant at 12 months and thereafter (Supplementary Table 8; Supplementary Fig. 3). A similar pattern on EQ-5D-5L usual activities score was seen in 520 propensity score-matched patients (including 118 patients receiving chemotherapy and 332 not receiving it) ( Supplementary  Fig. 4).

DISCUSSION
This study represents one of the largest prospective cohort studies conducted in older women with breast cancer and provides valuable data on tumour characteristics and health of older EBC patients. As expected, the majority of patients had relatively good prognosis tumours, with relatively low rates of nodal involvement and adverse biology as determined by ER and HER2 status.
Nonetheless, there remained a substantial proportion of high risk, fit patients (on baseline assessments), with a high relapse risk in their expected lifetime. Ensuring that these patients receive adequate treatment is a priority for clinicians.
A key finding of this study is that 27.8% of fit high-risk EBC older patients received chemotherapy. In the ACheW study 30% of highrisk EBC patients were offered chemotherapy and 17% received it. 23 Analyses of European and US registry data report similar findings. 5,24,25 These analyses did not consider recurrence risk (as determined by histopathological variables) and patients' fitness (to not only receive treatment but also to live long enough to benefit). The current study overcame these limitations, by defining recurrence risk and fitness, and still demonstrates low chemotherapy uptake. This may be due to uncertainty on chemotherapy benefit in older adults, toxicity concerns and patients' and carers' choice.
In order to investigate the survival benefits of chemotherapy for older EBC patients, we conducted survival analyses in those at high risk of recurrence. Ideally this question should be addressed by RCTs. Recruiting older patients into RCTs comparing different chemotherapy regimens is feasible, 26 but trials comparing chemotherapy with no chemotherapy have failed to recruit. 27,28 Moreover, older patients enrolled in RCTs may be fitter and not necessarily representative of a real-world population. 6 In contrast, this cohort study recruited well, and recruited patients with a broad fitness range.
Our analyses attempted to correct for confounders, specifically the fact that younger, fitter patients might be more likely to receive chemotherapy, but also are biologically more likely to survive longer irrespective of chemotherapy effect. This effect is perhaps most apparent when comparing the unmatched and matched OS analyses (Fig. 2a, b).
In the high-risk population chemotherapy reduced the risks of metastatic recurrence, which did not translate into better survival. This may be because the benefit was modest and the fact that median OS for ER-positive metastatic disease patients often exceeds 3 years with contemporary therapies. 29 Irrespective, a reduction in metastatic relapses, with their symptomatic, psychological and financial implications, may be sufficient grounds on which to offer treatment even in the absence of a survival benefit. Longer term follow-up will be required to further explore this.
Chemotherapy benefits are small for most ER-positive, HER2negative EBC patients. Therefore, we performed exploratory analyses in patients with the more chemotherapy-sensitive subtypes, i.e. ERnegative and HER2-positive disease. In ER-negative EBC patients there was an apparent reduction of breast cancer deaths with chemotherapy. These data are consistent with an US SEER analysis suggesting that adjuvant chemotherapy benefit in older patients were restricted to those with ER-negative disease. 28,30 In HER2positive EBC patients, fewer breast cancer deaths occurred in those who received chemotherapy with or without trastuzumab although the differences were not statistically significant in a matched analysis. This could be explained by the small numbers in this subgroup analysis. However, a retrospective study demonstrated that HER2-positive EBC older patients do not have inferior long-term outcomes compared with younger adults not receiving chemotherapy. 31 Low Ki67 and high bcl2 expression in the older cohort of HER2-positive patients might explain this better prognosis and also relative chemo-resistance. 31 Our study found that mortality rates from chemotherapy were very low and side effects consistent with previous analyses. 32 Follow-up of the cohort is planned at 10 years and may provide data about longer term benefits, although it should be recognised that with longer follow-up competing mortality causes are likely have a greater impact.
Our analysis also demonstrates that chemotherapy has a significant negative impact at 6 months on QoL, which is a meaningful endpoint in the context of a more limited survival benefit and increased risk of toxicities in this population. However, this effect resolves at 12 months consistent with previous findings in smaller or younger cohorts of patients 33,34 and is described in a more extensive analysis performed on this patient cohort. 18 A key strength of this study is that patients were recruited from a broad range of academic and general centres across the UK, and were likely to reflect contemporary practice and outcomes. However, despite the inclusive entry criteria and low level of intervention there was still the possibility of selection bias. In a separate analysis of this study we found that patients who did not enter the trial following screening were older and had worse functional ability. 35 Also, as patients were not randomised, unmeasured variables might have influenced our findings despite propensity score matching. The extent to which these data reflect practice and outcomes outside of the UK is unknown, although some published data do appear comparable. 24,25 In summary, this study demonstrates that there are a significant number of older but fit patients with high-risk EBC who are not receiving adjuvant chemotherapy. Some of these patients, particularly those with ER-negative disease, may derive benefit from chemotherapy. Clearly the benefits need to be discussed in the context of potential side effects and the transient negative impact on QoL. Nonetheless, it is important that individualised treatment decisions and discussions are made to ensure the best outcomes for older adults.